+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetics of oral moclobemide in healthy human subjects and effects on monoamine oxidase activity in platelets and excretion of urine monoamine metabolites



Pharmacokinetics of oral moclobemide in healthy human subjects and effects on monoamine oxidase activity in platelets and excretion of urine monoamine metabolites



European Journal of Clinical Pharmacology 28(1): 89-96



The plasma concentrations of the MAO[monoamine oxidase]-inhibitor moclobemide (Ro 11-1163) [an antipsychotic drug] were determined in 6 healthy male subjects after oral (tablets) administration. Effects on MAO activity in platelets and excretion of monoamine metabolites in urine were investigated. The design of the study was a double-blind cross-over study with single oral doses of placebo, 50, 100 and 200 mg of moclobemide. The elimination profile of the drug showed that the half life t1/2 of the unchanged drug ranged between 1 and 2 h except in one subject with a half-life of about 4 h. The mean bioavailability calculated using flow model concepts was .hivin.F = 0.43 after 50 mg, .hivin.F = 0.47 after 100 mg and .hivin.F = 0.59 after 200 mg. The outlier with a t1/2 of 4 h had a bioavailability of more than 0.80 after all 3 doses. The slightly increasing bioavailability with higher doses was interpreted as evidence of saturable hepatic first-pass elimination of the drug. MAO activity in platelets was measured before and 2, 6 and 24 h after drug administration. No inhibition of platelet MAO was obtained at any point in time or dose level, as to be expected since moclobemide preferentially inhibits MAO A. Urine excretion of the monoamine metabolites homovanilic acid (HVA), dihydroxyphenylacetic acid (DOPAC), 3-methoxy-4-hydroxy-phenylglycol (MOPEG) and 5-hydroxyindoleacetic acid (5-HIAA) was followed during 48 h after placebo, 50 and 200 mg of moclobemide. Time but not dose contributed significantly to the variability in excretion of the monoamine metabolites. An apparent reduction of HVA and DOPAC levels was obtained in the early phase after the administration of 200 mg of moclobemide. In 1 subject with a mild drug reaction a pronounced decrease in the levels of all the metabolites was obtained. In the other 5 subjects, the compound was very well tolerated with a few reported side-effects like increased activity, somnolence or sweatings. There was a slight but significant increase in blood pressure following 50 and 100 mg but not 200 mg of moclobemide.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006096285

Download citation: RISBibTeXText


Related references

Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. European Journal of Clinical Pharmacology 28(1): 89-95, 1985

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. British Journal of Clinical Pharmacology 30(6): 805-816, 1990

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. British Journal of Clinical Pharmacology 27(2): 243-256, 1989

Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. Psychopharmacology 106 Suppl: S68-S70, 1992

Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. Journal Of Neural Transmission General Section. 101(1-3): 83-94, 1995

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. International Journal of Neuropsychopharmacology 19(1), 2016

Effect of oral contraceptives on platelet monoamine oxidase, monoamine excretion, and adrenocortical function. Clinical Pharmacology and Therapeutics 20(6): 670-675, 1976

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clinical Pharmacokinetics 29(5): 292-332, 1995

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202, 1993

Monoamine oxidase inhibitors effect on human plasma melatonin blood platelet serotonin content and monoamine oxidase activity. Journal of Clinical Pharmacology 26(7): 552, 1986

Immunocytochemical localization of serotonin, monoamine oxidase and assessment of monoamine oxidase activity in human dental pulp. Brain Research 853(2): 374-376, Jan 24, 2000

Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity. Neuroendocrinology 34(4): 245-251, 1982

Early effects of monoamine oxidase inhibitors on dopamine metabolism and monoamine oxidase activity in the neostriatum of the rat. Journal of Neural Transmission 34(4): 279-289, 1973

Reduced monoamine oxidase activity in blood platelets from insulin-dependent diabetic subjects. Diabetes 28(5): 455-456, 1979

Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission. Supplementum 26: 97-104, 1988